With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already dynamic autoimmune therapy market will only increase. The first biosimilars to launch in this therapy area (infliximab  and Benepali ) have now been available for several years in Europe, and their uptake has been robust. With more adalimumab biosimilars forecast to launch in Europe over the next year, it will be critical for stakeholders active in the immune space to understand the dynamics of how adalimumab biosimilars will affect the uptake of the reference brand, Humira (AbbVie), and other originator biologics. Along with physician awareness of, familiarity with, and perceptions of biosimilars in general and the launched adalimumab biosimilars in particular, we explore the drivers of and barriers to the uptake of adalimumab biosimilars in Germany. We discuss promotional efforts, as well as prescriber and nonprescriber profiles, and benchmark the agents against other available biosimilars to better understand the dynamics of the German biosimilar market.
Are German physicians aware of Amgevita, Imraldi, Hulio, and Hyrimoz?
What is driving and will drive the uptake of adalimumab biosimilars in Germany? What is the current level of use of Amgevita, Imraldi, Hulio, and Hyrimoz, and how will this use change over time?
Have German physicians experienced pressure to prescribe Amgevita, Imraldi, Hulio, and/or Hyrimoz to patients?
What promotional messages are sales representatives using with the reference brand Humira and the adalimumab biosimilars Amgevita, Imraldi, Hulio, and Hyrimoz?
Emerging Biosimilars is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch. The research captures physicians’ awareness, perceptions, and use of biosimilars, as well as their impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Wave 1: February 2019
Wave 2: July 2019
Wave 3: TBC 2020
Survey of 30 rheumatologists, 30 gastroenterologists, and 30 dermatologists
Key metrics included
Unaided and aided awareness of Amgevita, Imraldi, Hulio, and Hyrimoz
Familiarity with and impressions of Amgevita, Imraldi, Hulio, and Hyrimoz
Prescriber and nonprescriber profiles
Willingness to prescribe Amgevita, Imraldi, Hulio, and Hyrimoz
Performance of Amgevita, Imraldi, Hulio, and Hyrimoz on key attributes
Sales representative frequency, reach, and satisfaction
Benchmarking against previously launched biosimilars